A Phase 1/2 interventional study of ION440 and Sham procedure in Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome, sponsored by Ionis Pharmaceuticals, Inc.. Recruiting at 12 sites in 5 countries. Open to male participants aged 2 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-08.
Sponsored by Ionis Pharmaceuticals, Inc. · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 55 studies in Rett Syndrome with a site in United States — 11 open to participants now, 21 under way, 5 of them phase 3. Rett Syndrome · United States.
Among the 55 studies in Rett Syndrome with a site in United States, this one is the 15th largest by planned enrollment of the 34 interventional ones that give a count, is one of 4 that started in 2024, is one of 2 in phase 1/2, reaches primary completion later than 11 of the 20 other live ones, and was the 46th registered.
96 studies on the registry are indexed under Rett Syndrome; 19 are open to participants now.
Browse Rett Syndrome studies →11 of the 55 studies in Rett Syndrome with a site in United States are open now. Recruiting first, the newest first:
Biomed Industries, Inc. · Sites in United States, Australia
Ages 5–20 · Women only
UCB BIOSCIENCES, Inc. · Sites in United States, Belgium, China and 10 more countries
Ages 5–35
University of Rochester · Sites in United States
Ages 2+ · Healthy volunteers
University of Minnesota · Sites in United States
Ages 18–99
Children's Hospital of Philadelphia · Sites in United States
Ages 1–18 · Women only · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 14 Rett Syndrome studies recruiting now, 4 (29%) set no upper age limit and 7 (50%) stop at 75 or younger; 12 take children under 18; 3 take healthy volunteers.
This study: 2 Years to 65 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
55 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 15 · Phase 3 14
First in 2004; this study’s year is marked. 4 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 48 is above the median of 30 across 64 interventional studies indexed under Rett Syndrome.
Median enrollment 32 across the 34 interventional studies, 146 across the 21 observational. Of the 31 that completed or were terminated, 14 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 55 have an industry lead sponsor. The 10 most frequent:
Ionis Pharmaceuticals, Inc. is the lead sponsor of 118 studies on the registry; 10 are open to participants now.
Of its 49 completed or terminated interventional studies of FDA-regulated products, 22 (45%) have results posted.
Ionis Pharmaceuticals, Inc. has 2 studies filed under Rett Syndrome — fewer than ten, so there is no comparison to draw.
10 of the studies in Rett Syndrome with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06840496Phase 3Biomed Industries, Inc.To Investigate the Efficacy of Treatment With Oral NA-921 (Bionetide) Versus Placebo in Females With Rett Syndrome | 2027-09-30 |
| NCT06338267Rett Syndrome Research TrustValidating Innovative Biosensors for Rett Autonomic Symptom Tracking | 2026-11 |
| NCT03655223RTI InternationalEarly Check: Expanded Screening in Newborns | 2026-11-30 |
| NCT06139172Rush University Medical CenterWeb Intervention for Parents of Youth With Genetic Syndromes (WINGS) | 2026-12 |
| NCT05012475Georgetown UniversityMeasuring Impact of Computer Gaming on Arm Use in Rett Syndrome | 2026-12-31 |
Add all 10 to your calendar (.ics) → With an account.
Among the 55 studies in Rett Syndrome with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary purpose of this study is to evaluate the safety and tolerability of ION440.
This is a phase 1-2 randomized, double-blind, sham-controlled, multiple-ascending dose (MAD) study to evaluate ION440 in pediatric and adult participants with MECP2 Duplication Syndrome (MDS) and will be conducted in two parts. During Part 1 (MAD) (36 weeks), participants will be randomized in a 3:1 ratio to receive ION440 or sham. Individuals who complete Part 1 may enter Part 2, an open label long-term extension study (LTE), where they will receive ION440 for up to approximately 156 weeks. Multiple dose cohorts (Dose A, Dose B, and Dose C) will be evaluated in the study.
All dosing cohorts will be further subdivided by age. Sub cohort A will include participants 8 through 65 years of age, and sub cohort B will include participants 2 through 7 years of age. Dosing cohorts will be enrolled sequentially with sub cohort A initiating prior to sub cohort B.
Key Inclusion criteria for Part 1:
Males aged ≥ 2 to ≤ 65 years, depending on specific cohort and group, at the time of .
Key Exclusion criteria for Part 1:
Key Inclusion criteria for Part 2:
Key Exclusion criteria for Part 2:
1. Has developed any concomitant disease (e.g., gastrointestinal, renal, hepatic, endocrine, respiratory, or cardiovascular system disease) or condition or circumstance, or any finding during Part 1/MAD that, in the opinion of the Investigator, makes the participant unsuitable for continued treatment (e.g., could interfere with the conduct of the study or that would pose an unacceptable risk to the participant in this study).
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive ION440 intrathecally at Dose A during Part 1/MAD, followed by ION440 Dose A during Part 2/LTE.
Drug: ION440
Participants will receive ION440 intrathecally at Dose B during Part 1/MAD, followed by ION440 Dose B during Part 2/LTE.
Drug: ION440
Participants will receive ION440 intrathecally at Dose C during Part 1/MAD, followed by ION440 Dose C during Part 2/LTE.
Drug: ION440
During the Part 1/MAD period, a lumbar procedure (LP) will be performed at the same frequency as ION440 administration. Participants will not receive ITB injections during this period. It will be followed by the open-label Part 2/LTE period, where participants will receive ION440 at the same dose as their enrolled cohort (e.g. Dose A, Dose B or Dose C).
Procedure: Sham procedure
ION440 will be administered by intrathecal bolus (ITB) injection.
An LP will be performed with CSF collection but will not be followed by the administration of study treatment by ITB injection.
Part 1: Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
Time frame: Up to approximately 36 weeks
Part 1: Number of Participants With Clinically Significant Change From Baseline in Vital Signs
Time frame: Baseline up to approximately 36 weeks
Part 1: Number of Participants With Clinically Significant Change From Baseline in Physical and Neurological Examination Findings
Time frame: Baseline up to approximately 36 weeks
Part 1: Number of Participants With Clinically Significant Change from Baseline in Laboratory Assessments
Time frame: Baseline up to approximately 36 weeks
Part 1: Number of Participants With Clinically Significant Change From Baseline in Electrocardiogram (ECG)
Time frame: Baseline up to approximately 36 weeks
Part 2: Number of Participants With TEAEs
Time frame: Up to approximately 192 weeks
Part 2: Number of Participants With Clinically Significant Change From Baseline in Vital Signs
Time frame: Baseline up to approximately 192 weeks
Part 2: Number of Participants With Clinically Significant Change From Baseline in Physical and Neurological Examination Findings
Time frame: Baseline up to approximately 192 weeks
Part 2: Number of Participants With Clinically Significant Change from Baseline in Laboratory Assessments
Time frame: Baseline up to approximately 192 weeks
Part 2: Number of Participants With Clinically Significant Change From Baseline in ECG
Time frame: Baseline up to approximately 192 weeks
Part 1: Maximum Observed Concentration (Cmax) of ION440 in Plasma
Time frame: Pre-dose and at multiple points post-dose up to Week 36
Part 1: Area Under the Concentration-time Curve (AUC) of ION440 in Plasma
Time frame: Pre-dose and at multiple points post-dose up to Week 36
Part 1: Plasma Terminal Elimination Half-life (t½) of ION440
Time frame: Pre-dose and at multiple points post-dose up to Week 36
Part 1: Trough Concentration (Ctrough) of ION440 in Plasma and CSF
Time frame: Pre-dose and at multiple points post-dose up to Week 36
Part 1: Plasma Concentration of ION440
Time frame: Pre-dose and at multiple points post-dose up to Week 36
Part 2: Trough Concentration (Ctrough) of ION440 in Plasma and CSF
Time frame: Up to approximately 192 weeks
Plan to share: Yes — Ionis may share anonymized individual participant data, aggregated clinical data, and other types of data that support the results in this study. Data requests from qualified researchers will be considered once all three of the following criteria are met: (1) 12 months from marketing approval of the study drug in both the United States and European Union; (2) 18 months from conclusion of the study; and (3) 6 months from publication of study article. Access would be via a secure environment and is contingent upon approval of a research proposal and entry into an appropriate data use agreement. Requests to access data can be submitted via the website https://vivli.org/ourmember/ionis/.
Data sharing details ↗ · vivli.org
No publications or documents are linked to this record.
Started Oct 2024 (actual). Primary completion is estimated for Sep 2027, 35 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.